Curis Lifesciences opened lower at ₹182.35, compared with its previous close of ₹191.90. During today's session, the stock has traded between ₹182.35 and ₹184.00, with an average traded price of ₹182.83. It is currently showing a downward intraday trend.
return calculator
Time Period
An investment of ₹10,000 made 1 year ago in Curis Lifesciences is now worth
₹ 12,950.00
giving a profit of
₹ 2,950.00 (29.50%)
invest now
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
-9.30 (-4.85%)
Day High
₹184.00
Day Low
₹182.35
Day Open
₹182.35
Prev Close
₹191.90
Volume
9,000
Value Traded
₹0.16 Cr
1W Return
-11.79%
1M Return
-7.94%
3M Return
81.33%
6M Return
70.26%
1Y Return
29.50%
Fundamentals
Market Cap (₹ Cr.)
148
PE Ratio
22.40
PB Ratio
3.28
Dividend Yield
-
ROE
14.60%
ROCE
19.77%
Book Value (₹)
58.58
Face Value (₹)
10.00
EPS (TTM)
24.00
Industry PE
-
Beta
-
Debt to Equity
-
Investment Returns
1 Week
-11.79%
6 Week
-
1 Month
-7.94%
3 Month
81.33%
9 Month
48.21%
Financials
Yearly
All values in ₹ crores
No data available.
Share Holding Pattern
Promoter68.03%
FII1.19%
DII5.80%
Retails & Others14.38%
Updates
6Jul
Curis Lifesciences accepts resignation of independent director
Curis Lifesciences accepted the resignation of Mr. Chand Rameshbhai Kanabar as Independent Director from its Board effective July 3, 2026, due to increased professional commitments. The company confirmed there are no other material reasons for his resignation. The disclosure was made in compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
3mo ago
4Jul
Curis Lifesciences fined Rs 5,900 by NSE for delayed compliance
Curis Lifesciences has been fined Rs 5,900 by the National Stock Exchange of India Limited (NSE) for delayed compliance with Regulation 23(9) of the SEBI Listing Regulations for the year ended March 2026. The penalty, which includes GST, was communicated via email on June 30, 2026, and is payable within 15 days. The company disclosed that the financial impact is limited to the fine amount.
3mo ago
3Jun
Curis Lifesciences promoters report no share encumbrance in FY26
Curis Lifesciences promoters Jaimik Mansukhlal Patel, Dharmesh Dasharathbhai Patel, Piyush Gordhanbhai Antala, and Siddhant Jayantibhai Pawasia declared no new encumbrances on shares for FY26. The disclosure was made to the NSE and the company's Audit Committee on April 3, 2026, under SEBI Takeover Regulations.
4mo ago
1Jun
Curis Lifesciences FY26 net profit rises 11.4% to ₹691.63 lakh
Curis Lifesciences reported an 11.4% rise in FY26 net profit to ₹691.63 lakh, driven by a 20.6% increase in revenue to ₹6062.88 lakh. The Board approved the audited standalone financial results for the year ended March 31, 2026. The company also announced a strategic investment in Uninova Lifesciences Private Limited.
